Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 90

1.

Identifying environmental chemicals as agonists of the androgen receptor by using a quantitative high-throughput screening platform.

Lynch C, Sakamuru S, Huang R, Stavreva DA, Varticovski L, Hager GL, Judson RS, Houck KA, Kleinstreuer NC, Casey W, Paules RS, Simeonov A, Xia M.

Toxicology. 2017 Jun 15;385:48-58. doi: 10.1016/j.tox.2017.05.001. Epub 2017 May 4.

PMID:
28478275
2.

High fat diet-induced changes of mouse hepatic transcription and enhancer activity can be reversed by subsequent weight loss.

Siersbæk M, Varticovski L, Yang S, Baek S, Nielsen R, Mandrup S, Hager GL, Chung JH, Grøntved L.

Sci Rep. 2017 Jan 10;7:40220. doi: 10.1038/srep40220.

3.

Novel cell-based assay for detection of thyroid receptor beta-interacting environmental contaminants.

Stavreva DA, Varticovski L, Levkova L, George AA, Davis L, Pegoraro G, Blazer V, Iwanowicz L, Hager GL.

Toxicology. 2016 Aug 10;368-369:69-79. doi: 10.1016/j.tox.2016.08.012. Epub 2016 Aug 12.

4.

Targeted BMI1 inhibition impairs tumor growth in lung adenocarcinomas with low CEBPα expression.

Yong KJ, Basseres DS, Welner RS, Zhang WC, Yang H, Yan B, Alberich-Jorda M, Zhang J, de Figueiredo-Pontes LL, Battelli C, Hetherington CJ, Ye M, Zhang H, Maroni G, O'Brien K, Magli MC, Borczuk AC, Varticovski L, Kocher O, Zhang P, Moon YC, Sydorenko N, Cao L, Davis TW, Thakkar BM, Soo RA, Iwama A, Lim B, Halmos B, Neuberg D, Tenen DG, Levantini E.

Sci Transl Med. 2016 Aug 3;8(350):350ra104. doi: 10.1126/scitranslmed.aad6066.

PMID:
27488898
5.

Genome-Wide Chromatin Landscape Transitions Identify Novel Pathways in Early Commitment to Osteoblast Differentiation.

Thompson B, Varticovski L, Baek S, Hager GL.

PLoS One. 2016 Feb 18;11(2):e0148619. doi: 10.1371/journal.pone.0148619. eCollection 2016.

6.

Targeted H3R26 deimination specifically facilitates estrogen receptor binding by modifying nucleosome structure.

Guertin MJ, Zhang X, Anguish L, Kim S, Varticovski L, Lis JT, Hager GL, Coonrod SA.

PLoS Genet. 2014 Sep 11;10(9):e1004613. doi: 10.1371/journal.pgen.1004613. eCollection 2014 Sep.

7.

Prevalent glucocorticoid and androgen activity in US water sources.

Stavreva DA, George AA, Klausmeyer P, Varticovski L, Sack D, Voss TC, Schiltz RL, Blazer VS, Iwanowicz LR, Hager GL.

Sci Rep. 2012;2:937. doi: 10.1038/srep00937. Epub 2012 Dec 6.

8.

Critical role for the receptor tyrosine kinase EPHB4 in esophageal cancers.

Hasina R, Mollberg N, Kawada I, Mutreja K, Kanade G, Yala S, Surati M, Liu R, Li X, Zhou Y, Ferguson BD, Nallasura V, Cohen KS, Hyjek E, Mueller J, Kanteti R, El Hashani E, Kane D, Shimada Y, Lingen MW, Husain AN, Posner MC, Waxman I, Villaflor VM, Ferguson MK, Varticovski L, Vokes EE, Gill P, Salgia R.

Cancer Res. 2013 Jan 1;73(1):184-94. doi: 10.1158/0008-5472.CAN-12-0915. Epub 2012 Oct 24. Erratum in: Cancer Res. 2013 Jul 15;73(14):4594.

9.

P6981, an arylstibonic acid, is a novel low nanomolar inhibitor of cAMP response element-binding protein binding to DNA.

Zhao J, Stagno JR, Varticovski L, Nimako E, Rishi V, McKinnon K, Akee R, Shoemaker RH, Ji X, Vinson C.

Mol Pharmacol. 2012 Nov;82(5):814-23. doi: 10.1124/mol.112.080820. Epub 2012 Jul 31.

10.

Chromatin in time and space.

Hager GL, Varticovski L.

Biochim Biophys Acta. 2012 Jul;1819(7):631. doi: 10.1016/j.bbagrm.2012.05.002. No abstract available.

PMID:
22677544
11.

Dietary energy balance modulates epithelial-to-mesenchymal transition and tumor progression in murine claudin-low and basal-like mammary tumor models.

Dunlap SM, Chiao LJ, Nogueira L, Usary J, Perou CM, Varticovski L, Hursting SD.

Cancer Prev Res (Phila). 2012 Jul;5(7):930-42. doi: 10.1158/1940-6207.CAPR-12-0034. Epub 2012 May 15.

12.

Complex dynamics of transcription regulation.

Stavreva DA, Varticovski L, Hager GL.

Biochim Biophys Acta. 2012 Jul;1819(7):657-66. doi: 10.1016/j.bbagrm.2012.03.004. Epub 2012 Mar 28. Review.

13.

Chaperone-mediated autophagy is required for tumor growth.

Kon M, Kiffin R, Koga H, Chapochnick J, Macian F, Varticovski L, Cuervo AM.

Sci Transl Med. 2011 Nov 16;3(109):109ra117. doi: 10.1126/scitranslmed.3003182.

14.

Schedule-dependent synergy of histone deacetylase inhibitors with DNA damaging agents in small cell lung cancer.

Luchenko VL, Salcido CD, Zhang Y, Agama K, Komlodi-Pasztor E, Murphy RF, Giaccone G, Pommier Y, Bates SE, Varticovski L.

Cell Cycle. 2011 Sep 15;10(18):3119-28. Epub 2011 Sep 15.

15.

Prolonged drug selection of breast cancer cells and enrichment of cancer stem cell characteristics.

Calcagno AM, Salcido CD, Gillet JP, Wu CP, Fostel JM, Mumau MD, Gottesman MM, Varticovski L, Ambudkar SV.

J Natl Cancer Inst. 2010 Nov 3;102(21):1637-52. doi: 10.1093/jnci/djq361. Epub 2010 Oct 8.

16.

Molecular characterisation of side population cells with cancer stem cell-like characteristics in small-cell lung cancer.

Salcido CD, Larochelle A, Taylor BJ, Dunbar CE, Varticovski L.

Br J Cancer. 2010 May 25;102(11):1636-44. doi: 10.1038/sj.bjc.6605668. Epub 2010 Apr 27.

17.

The arylstibonic acid compound NSC13746 disrupts B-ZIP binding to DNA in living cells.

Heyerdahl SL, Rozenberg J, Jamtgaard L, Rishi V, Varticovski L, Akah K, Scudiero D, Shoemaker RH, Karpova TS, Day RN, McNally JG, Vinson C.

Eur J Cell Biol. 2010 Jul;89(7):564-73. doi: 10.1016/j.ejcb.2009.11.029. Epub 2010 Apr 1.

PMID:
20362353
18.

Clinical and translational studies of a phase II trial of the novel oral Akt inhibitor perifosine in relapsed or relapsed/refractory Waldenstrom's macroglobulinemia.

Ghobrial IM, Roccaro A, Hong F, Weller E, Rubin N, Leduc R, Rourke M, Chuma S, Sacco A, Jia X, Azab F, Azab AK, Rodig S, Warren D, Harris B, Varticovski L, Sportelli P, Leleu X, Anderson KC, Richardson PG.

Clin Cancer Res. 2010 Feb 1;16(3):1033-41. doi: 10.1158/1078-0432.CCR-09-1837. Epub 2010 Jan 26.

19.

Microenvironmental modulation of asymmetric cell division in human lung cancer cells.

Pine SR, Ryan BM, Varticovski L, Robles AI, Harris CC.

Proc Natl Acad Sci U S A. 2010 Feb 2;107(5):2195-200. doi: 10.1073/pnas.0909390107. Epub 2010 Jan 13.

20.

A purine scaffold Hsp90 inhibitor destabilizes BCL-6 and has specific antitumor activity in BCL-6-dependent B cell lymphomas.

Cerchietti LC, Lopes EC, Yang SN, Hatzi K, Bunting KL, Tsikitas LA, Mallik A, Robles AI, Walling J, Varticovski L, Shaknovich R, Bhalla KN, Chiosis G, Melnick A.

Nat Med. 2009 Dec;15(12):1369-76. doi: 10.1038/nm.2059. Epub 2009 Nov 22.

21.

Hsp90 inhibitor PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer models.

Caldas-Lopes E, Cerchietti L, Ahn JH, Clement CC, Robles AI, Rodina A, Moulick K, Taldone T, Gozman A, Guo Y, Wu N, de Stanchina E, White J, Gross SS, Ma Y, Varticovski L, Melnick A, Chiosis G.

Proc Natl Acad Sci U S A. 2009 May 19;106(20):8368-73. doi: 10.1073/pnas.0903392106. Epub 2009 May 5.

22.

microRNA expression in the biology, prognosis, and therapy of Waldenström macroglobulinemia.

Roccaro AM, Sacco A, Chen C, Runnels J, Leleu X, Azab F, Azab AK, Jia X, Ngo HT, Melhem MR, Burwick N, Varticovski L, Novina CD, Rollins BJ, Anderson KC, Ghobrial IM.

Blood. 2009 Apr 30;113(18):4391-402. doi: 10.1182/blood-2008-09-178228. Epub 2008 Dec 12.

23.

HSP90 inhibitor, DMAG, synergizes with radiation of lung cancer cells by interfering with base excision and ATM-mediated DNA repair.

Koll TT, Feis SS, Wright MH, Teniola MM, Richardson MM, Robles AI, Bradsher J, Capala J, Varticovski L.

Mol Cancer Ther. 2008 Jul;7(7):1985-92. doi: 10.1158/1535-7163.MCT-07-2104.

24.

The chaperone-mediated autophagy receptor organizes in dynamic protein complexes at the lysosomal membrane.

Bandyopadhyay U, Kaushik S, Varticovski L, Cuervo AM.

Mol Cell Biol. 2008 Sep;28(18):5747-63. doi: 10.1128/MCB.02070-07. Epub 2008 Jul 21.

25.

Obesity accelerates mouse mammary tumor growth in the absence of ovarian hormones.

Nunez NP, Perkins SN, Smith NC, Berrigan D, Berendes DM, Varticovski L, Barrett JC, Hursting SD.

Nutr Cancer. 2008;60(4):534-41. doi: 10.1080/01635580801966195.

PMID:
18584488
26.

Rapamycin delays growth of Wnt-1 tumors in spite of suppression of host immunity.

Svirshchevskaya EV, Mariotti J, Wright MH, Viskova NY, Telford W, Fowler DH, Varticovski L.

BMC Cancer. 2008 Jun 21;8:176. doi: 10.1186/1471-2407-8-176.

27.

Lung cancer stem cells.

Pine SR, Marshall B, Varticovski L.

Dis Markers. 2008;24(4-5):257-66. Review.

28.

Molecular analysis reveals heterogeneity of mouse mammary tumors conditionally mutant for Brca1.

Wright MH, Robles AI, Herschkowitz JI, Hollingshead MG, Anver MR, Perou CM, Varticovski L.

Mol Cancer. 2008 Apr 7;7:29. doi: 10.1186/1476-4598-7-29.

29.

Single-step doxorubicin-selected cancer cells overexpress the ABCG2 drug transporter through epigenetic changes.

Calcagno AM, Fostel JM, To KK, Salcido CD, Martin SE, Chewning KJ, Wu CP, Varticovski L, Bates SE, Caplen NJ, Ambudkar SV.

Br J Cancer. 2008 May 6;98(9):1515-24. doi: 10.1038/sj.bjc.6604334. Epub 2008 Apr 1.

30.

Brca1 breast tumors contain distinct CD44+/CD24- and CD133+ cells with cancer stem cell characteristics.

Wright MH, Calcagno AM, Salcido CD, Carlson MD, Ambudkar SV, Varticovski L.

Breast Cancer Res. 2008;10(1):R10. doi: 10.1186/bcr1855. Epub 2008 Feb 1.

31.

Novel indenoisoquinolines NSC 725776 and NSC 724998 produce persistent topoisomerase I cleavage complexes and overcome multidrug resistance.

Antony S, Agama KK, Miao ZH, Takagi K, Wright MH, Robles AI, Varticovski L, Nagarajan M, Morrell A, Cushman M, Pommier Y.

Cancer Res. 2007 Nov 1;67(21):10397-405. Erratum in: Cancer Res. 2007 Dec 15;67(24):12034.

32.

A phase II clinical trial with cytotropic heterogeneous molecular lipids (CHML) for patients with hepatic malignancies.

Chen XC, Yu B, Dong JC, Gu YX, Chen L, Wu QZ, Hou NP, Liu JX, Xu JT, Jin RX, Jin GQ, Yang XD, Cao YW, Tan JJ, Zhu B, Shen JC, Xu Z, Varticovski L, Wang XW.

Anticancer Res. 2007 May-Jun;27(3B):1593-600.

33.

Accelerated preclinical testing using transplanted tumors from genetically engineered mouse breast cancer models.

Varticovski L, Hollingshead MG, Robles AI, Wu X, Cherry J, Munroe DJ, Lukes L, Anver MR, Carter JP, Borgel SD, Stotler H, Bonomi CA, Nunez NP, Hursting SD, Qiao W, Deng CX, Green JE, Hunter KW, Merlino G, Steeg PS, Wakefield LM, Barrett JC.

Clin Cancer Res. 2007 Apr 1;13(7):2168-77.

34.

Inhibitor of growth 4 suppresses cell spreading and cell migration by interacting with a novel binding partner, liprin alpha1.

Shen JC, Unoki M, Ythier D, Duperray A, Varticovski L, Kumamoto K, Pedeux R, Harris CC.

Cancer Res. 2007 Mar 15;67(6):2552-8.

35.

The obesity-cancer link: lessons learned from a fatless mouse.

Hursting SD, Nunez NP, Varticovski L, Vinson C.

Cancer Res. 2007 Mar 15;67(6):2391-3. Review.

36.

Harnessing genetically engineered mouse models for preclinical testing.

Robles AI, Varticovski L.

Chem Biol Interact. 2008 Jan 30;171(2):159-64. Epub 2007 Feb 8. Review.

PMID:
17362899
37.
38.

Bisindenoisoquinoline bis-1,3-{(5,6-dihydro-5,11-diketo-11H-indeno[1,2-c]isoquinoline)-6-propylamino}propane bis(trifluoroacetate) (NSC 727357), a DNA intercalator and topoisomerase inhibitor with antitumor activity.

Antony S, Agama KK, Miao ZH, Hollingshead M, Holbeck SL, Wright MH, Varticovski L, Nagarajan M, Morrell A, Cushman M, Pommier Y.

Mol Pharmacol. 2006 Sep;70(3):1109-20. Epub 2006 Jun 23.

39.

Accelerated tumor formation in a fatless mouse with type 2 diabetes and inflammation.

Nunez NP, Oh WJ, Rozenberg J, Perella C, Anver M, Barrett JC, Perkins SN, Berrigan D, Moitra J, Varticovski L, Hursting SD, Vinson C.

Cancer Res. 2006 May 15;66(10):5469-76.

40.

The p53 tumor suppressor network is a key responder to microenvironmental components of chronic inflammatory stress.

Staib F, Robles AI, Varticovski L, Wang XW, Zeeberg BR, Sirotin M, Zhurkin VB, Hofseth LJ, Hussain SP, Weinstein JN, Galle PR, Harris CC.

Cancer Res. 2005 Nov 15;65(22):10255-64.

41.

Computerized case history--an effective tool for management of patients and clinical trials.

Shklovsky-Kordi N, Zingerman B, Rivkind N, Goldberg S, Davis S, Varticovski L, Krol M, Kremenetzkaia AM, Vorobiev A, Serebriyskiy I.

Stud Health Technol Inform. 2005;116:53-8.

PMID:
16160235
42.

Identification of carboxypeptidase E and gamma-glutamyl hydrolase as biomarkers for pulmonary neuroendocrine tumors by cDNA microarray.

He P, Varticovski L, Bowman ED, Fukuoka J, Welsh JA, Miura K, Jen J, Gabrielson E, Brambilla E, Travis WD, Harris CC.

Hum Pathol. 2004 Oct;35(10):1196-209.

PMID:
15492986
43.

The knockout mouse project.

Austin CP, Battey JF, Bradley A, Bucan M, Capecchi M, Collins FS, Dove WF, Duyk G, Dymecki S, Eppig JT, Grieder FB, Heintz N, Hicks G, Insel TR, Joyner A, Koller BH, Lloyd KC, Magnuson T, Moore MW, Nagy A, Pollock JD, Roses AD, Sands AT, Seed B, Skarnes WC, Snoddy J, Soriano P, Stewart DJ, Stewart F, Stillman B, Varmus H, Varticovski L, Verma IM, Vogt TF, von Melchner H, Witkowski J, Woychik RP, Wurst W, Yancopoulos GD, Young SG, Zambrowicz B.

Nat Genet. 2004 Sep;36(9):921-4.

44.

A direct binding site for Grb2 contributes to transformation and leukemogenesis by the Tel-Abl (ETV6-Abl) tyrosine kinase.

Million RP, Harakawa N, Roumiantsev S, Varticovski L, Van Etten RA.

Mol Cell Biol. 2004 Jun;24(11):4685-95.

45.
46.

Histone deacetylase inhibitors promote STI571-mediated apoptosis in STI571-sensitive and -resistant Bcr/Abl+ human myeloid leukemia cells.

Yu C, Rahmani M, Almenara J, Subler M, Krystal G, Conrad D, Varticovski L, Dent P, Grant S.

Cancer Res. 2003 May 1;63(9):2118-26.

47.

Mechanisms by which cAMP increases bile acid secretion in rat liver and canalicular membrane vesicles.

Misra S, Varticovski L, Arias IM.

Am J Physiol Gastrointest Liver Physiol. 2003 Aug;285(2):G316-24. Epub 2003 Apr 17.

48.

Mechanism by which cAMP activates PI3-kinase and increases bile acid secretion in WIF-B9 cells.

Kagawa T, Varticovski L, Sai Y, Arias IM.

Am J Physiol Cell Physiol. 2002 Dec;283(6):C1655-66. Epub 2002 Aug 1.

49.
50.

Water-soluble HPMA copolymer-wortmannin conjugate retains phosphoinositide 3-kinase inhibitory activity in vitro and in vivo.

Varticovski L, Lu ZR, Mitchell K, de Aos I, Kopecek J.

J Control Release. 2001 Jul 6;74(1-3):275-81.

PMID:
11489507

Supplemental Content

Loading ...
Support Center